Drugging the ‘undruggable’ cancer targets

Dang, Chi V., Reddy, E. Premkumar, Shokat, Kevan M., Soucek, Laura·2017·Nature Reviews Cancer

DOI 10.1038/nrc.2017.36

Cited by (949)

Items 101–200 of 949

Extracellular vesicles in cancer nanomedicine
Tarasov, Vadim V., Svistunov, Andrey A., Chubarev, Vladimir N., Dostdar, Samira A., Sokolov, Alexander V., Brzecka, Anna, Sukocheva, Olga, Neganova, Margarita E., Klochkov, Sergey G., Somasundaram, Siva G. et al. · 2021 · Seminars in Cancer Biology
CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research
Fahreddin Palaz, Ali Kerem Kalkan, Özgür Can, Ayça Nur Demir, Abdullah Tozluyurt, Ahsen Özcan, Mehmet Özsöz · 2021 · ACS Synthetic Biology
Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer
Martin Pichler, Cristian Rodriguez‐Aguayo, Su Youn Nam, Mihnea Paul Dragomir, Recep Bayraktar, Simone Anfossi, Erik Knutsen, Cristina Ivan, Enrique Fuentes‐Mattei, Sang Kil Lee et al. · 2020 · Gut
Inorganic Nanomaterial‐Mediated Gene Therapy in Combination with Other Antitumor Treatment Modalities
Guanyou Lin, Richard A. Revia, Miqin Zhang · 2020 · Advanced Functional Materials
MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1
Tessa M. Popay, Jing Wang, Clare M. Adams, Gregory Caleb Howard, Simona G. Codreanu, Stacy D. Sherrod, JOHN A. JUN. MCLEAN, Lance R. Thomas, Shelly L. Lorey, Yuichi Machida et al. · 2021 · eLife
Photopharmacology and photoresponsive drug delivery
Yuwei Liu, Tianyi Wang, Weiping Wang · 2025 · Chemical Society Reviews
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
Yuan Ren, Chengfeng Bi, Xiaohong Zhao, Tint Lwin, Cheng Wang, Yuan Ji, Ariosto Siqueira Silva, Bijal Dinesh Shah, Bin Fang, Tao Li et al. · 2018 · Journal of Clinical Investigation
Nanotechnology-Based Strategies to Overcome Current Barriers in Gene Delivery
Mirón-Barroso, Sofía, Domènech, Elena B., Trigueros, Sonia · 2021 · International Journal of Molecular Sciences
Targeting Cbl-b in cancer immunotherapy
Ryan C. Augustin, Riyue Bao, Jason J. Luke · 2023 · Journal for ImmunoTherapy of Cancer
GEPIA3: Enhanced drug sensitivity and interaction network analysis for cancer research
Yu-Jian Kang, Lingjie Pan, Yiyu Liu, Zhengqin Rong, Jiaxi Liu, Fenglin Liu · 2025 · Nucleic Acids Research
RNA‐binding motif protein 39 (RBM39): An emerging cancer target
Yuewei Xu, Anke M. Nijhuis, Hector C. Keun · 2020 · British Journal of Pharmacology
MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma
Ganna Oliynyk, María Victoria Ruiz-Pérez, Lourdes Sainero‐Alcolado, Johanna Dzieran, Hanna Zirath, Héctor Gallart‐Ayala, Craig Edward Wheelock, Henrik J. Johansson, Roland Nilsson, Janne Lehtiö et al. · 2019 · iScience
Targeting the β-catenin signaling for cancer therapy
Xue Zhang, Lei Wang, Yi Qu · 2020 · Pharmacological Research
Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance
Yazmin Brown, Susan Hua, Pradeep Singh Tanwar · 2019 · The International Journal of Biochemistry & Cell Biology
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Michael Joe Duffy, John Paul Crown · 2020 · International Journal of Cancer
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Jing Gao, Lei Yang, Shumin Lei, Feng Zhou, Hui‐Jun Nie, Bo Peng, Tianfeng Xu, Xiaohua Chen, Xiaobao Yang, Chunquan Sheng et al. · 2023 · 中国科学通报：英文版
Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications
Alexander Chan, Andrew Tsourkas · 2023 · BME Frontiers
Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad‑spectrum cancer gene therapy - A review of molecular mechanisms for oncologists
Erlinda Maria Gordon, Joshua R. Ravicz, Seiya Liu, Sant P. Chawla, Frederick L. Hall · 2018 · Molecular and Clinical Oncology
Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
Anja Dölle, Bikash Adhikari, Andreas Krämer, Janik Weckesser, Nicola Berner, Lena M. Berger, Mathias Diebold, Magdalena M. Szewczyk, Dalia Baršytė-Lovejoy, C.H. Arrowsmith et al. · 2021 · Journal of Medicinal Chemistry
Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
Liuying Wang, Yongzhen Song, Hesong Wang, Xuan Zhang, Meng Wang, Jia He, Shuang Li, Liuchao Zhang, Kang Li, Lei Cao · 2023 · Pharmaceuticals
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, Hongmei Jiang, Yuetong Zhang, Siqi Gong, Jiaxin Wu, Bei Liu, Jianyou Shi, Yijun Gao · 2023 · Signal Transduction and Targeted Therapy
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
Edina Wang, Anabel Sorolla, Paula T. Cunningham, Heique Marlis Bogdawa, Samuel J. Beck, Emily Golden, Robert E. Dewhurst, Laura Florez, Mark N. Cruickshank, Katrin Hoffmann et al. · 2018 · Oncogene
Targeted delivery to macrophages and dendritic cells by chemically modified mannose ligand-conjugated siRNA
Keiji Uehara, Toshimasa Harumoto, Asana Makino, Yasuo Koda, Junko Iwano, Yasuhiro Suzuki, Mari Tanigawa, Hiroto Iwai, Kana Asano, Kana Kurihara et al. · 2022 · Nucleic Acids Research
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
Junichiro Yuda, Christine Will, Darren C. Phillips, Linu Abraham, Cory M. Alvey, Abraham Avigdor, Wayne R. Buck, Lauren M. Besenhofer, Erwin R. Boghaert, Dong Cheng et al. · 2023 · Communications Medicine
Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair
Linlin Yang, Changxian Shen, Adriana Estrada‐Bernal, Ryan N. Robb, Moumita Chatterjee, Nikhil Sebastian, Amy Webb, Xiaokui Molly Mo, Wei Chen, Sunil Krishnan et al. · 2021 · Nucleic Acids Research
Pharmacokinetics and Pharmacodynamics of GalNAc‐Conjugated siRNAs
Guohua An · 2023 · The Journal of Clinical Pharmacology
High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege
Casey R. Ager, Akash R. Boda, Kimal Rajapakshe, Spencer Thomas Lea, Maria Emilia Di Francesco, Priyamvada Jayaprakash, Ravaen Slay, Brittany Morrow, Rishika Prasad, Meghan A. Dean et al. · 2021 · Journal for ImmunoTherapy of Cancer
BET Proteins as Attractive Targets for Cancer Therapeutics
Joanna Sarnik, Tomasz Popławski, Paulina Tokarz · 2021 · International Journal of Molecular Sciences
KRAS Inhibitors– yes but what next? Direct targeting of KRAS– vaccines, adoptive T cell therapy and beyond
Misako Nagasaka, Bindu Rani Potugari, Alexis Nguyen, Ammar W. Sukari, Asfar Sohail Azmi, Sai‐Hong Ignatius Ou · 2021 · Cancer Treatment Reviews
LncRNA SNHG17 interacts with LRPPRC to stabilize c-Myc protein and promote G1/S transition and cell proliferation
Jin-Yu Liu, Yajing Chen, Huan-Hui Feng, Zhan‐Li Chen, Yunlong Wang, Jine Yang, Shi‐Mei Zhuang · 2021 · Cell Death and Disease
Machine Learning Informs RNA‐Binding Chemical Space**
Kamyar Yazdani, Deondre Jordan, Mo Yang, Christopher R. Fullenkamp, David R. Calabrese, Robert E. Boer, Thomas A. Hilimire, Timothy E. H. Allen, Rabia T. Khan, John S. Schneekloth · 2022 · Angewandte Chemie International Edition
Defining the condensate landscape of fusion oncoproteins
Swarnendu Tripathi, Hazheen K. Shirnekhi, Scott D. Gorman, Bappaditya Chandra, David W. Baggett, Cheon‐Gil Park, Ramiz Somjee, Benjamin Lang, Seyed Mohammad Hadi Hosseini, Brittany J. Pioso et al. · 2023 · Nature Communications
Selection of Nucleotide-Encoded Mass Libraries of Macrocyclic Peptides for Inaccessible Drug Targets
Kilian Colas, Daniel Bindl, Hiroaki Suga · 2024 · Chemical Reviews
Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer
Fang Huang, Kenneth E. Huffman, Zixi Wang, Xun Wang, Kailong Li, Feng Cai, Chendong Yang, Ling Cai, T. Shane Shih, Lauren G. Zacharias et al. · 2020 · Journal of Clinical Investigation
Molecular mechanisms and therapeutic targets in neuroblastoma
John Inge Johnsen, Cecilia H. Dyberg, Susanne M. Fransson, Malin Wickström · 2018 · Pharmacological Research
Stable tRNA halves can be sorted into extracellular vesicles and delivered to recipient cells in a concentration-dependent manner
Fabiana Gámbaro, Marco Li Calzi, Pablo Fagúndez, Bruno Costa, Gonzalo Greif, Emily R. Mallick, Shawn M. Lyons, Pavel V. Ivanov, Kenneth Whitaker Witwer, Alfonso Cayota et al. · 2019 · RNA Biology
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C. et al. · 2017 · OncoImmunology
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
Devon R. Blake, Angelina V. Vaseva, Richard G. Hodge, McKenzie P. Kline, Thomas S.K. Gilbert, Vikas Tyagi, Daowei Huang, Gabrielle C. Whiten, Jacob E. Larson, Xiaodong Wang et al. · 2019 · Science Signaling
Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape
Matilde Durán‐Lobato, Ana M. López-Estévez, Ana Sara Cordeiro, Tamara G. Dacoba, José Crecente‐Campo, Dolores Torres, Marı́a José Alonso · 2021 · Advanced Drug Delivery Reviews
Current strategies and progress for targeting the “undruggable” transcription factors
Jingjing Zhuang, Qian Liu, Dalei Wu, Lu Tie · 2022 · Acta Pharmacologica Sinica
Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
Tomonori Tamura, Masaharu Kawano, Itaru Hamachi · 2025 · Chemical Reviews
The rise of covalent proteolysis targeting chimeras
Ronen Gabizon, Nir London · 2021 · Current Opinion in Chemical Biology
Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential
Li Na Zhao, Mikael Björklund, Matias J. Caldez, Jie Zheng, Philipp Kaldis · 2021 · Oncogene
De novo design of peptide binders to conformationally diverse targets with contrastive language modeling
Suhaas Bhat, Kalyan Palepu, Lauren Hong, Yiwei Mao, Tianzheng Ye, Rema Iyer, Lin Zhao, Tianlai Chen, Sophia Vincoff, Rio Watson et al. · 2025 · Science Advances
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Adam J. Wolpaw, Richard W. Bayliss, Gabriele Büchel, Chi Van Dang, Martin Eilers, William Clay Gustafson, Gwenn M. Hansen, Natalia Jura, Stefan Knapp, Mark A. Lemmon et al. · 2021 · Cancer Research
Computer-Aided Drug Discovery for Undruggable Targets
Qi Sun, Hanping Wang, Juan Xie, Liying Wang, Junxi Mu, Junren Li, Yuhao Ren, Luhua Lai · 2025 · Chemical Reviews
Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins
Alexander Chan, Rebecca M. Haley, Mohd Altaf Najar, David Gonzalez-Martinez, Lukasz J. Bugaj, George M. Burslem, Michael J. Mitchell, Andrew Tsourkas · 2024 · Nature Communications
Temporal dynamics of Wnt-dependent transcriptome reveal an oncogenic Wnt/MYC/ribosome axis
Babita Madan, Nathan Harmston, Gahyathiri Nallan, Alex Montoya, Peter Allen Faull, Enrico G. Petretto, David M. Virshup · 2018 · Journal of Clinical Investigation
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
Evon Poon, Tong Liang, Yann Jamin, Susanne Walz, Colin Kwok, Anne Hakkert, Karen T. Barker, Zuzanna Urban‐Wójciuk, Khin Thway, Rhamy Zeid et al. · 2020 · Journal of Clinical Investigation
Activating KRAS mutations in arteriovenous malformations of the brain: frequency and clinicopathologic correlation
David S. Priemer, Alexander O. Vortmeyer, Shaobo Zhang, Hsim Yee Chang, Kendra L. Curless, Liang Cheng C · 2019 · Human Pathology
Alpha-Difluoromethylornithine, an Irreversible Inhibitor of Polyamine Biosynthesis, as a Therapeutic Strategy against Hyperproliferative and Infectious Diseases
Nicole LoGiudice, Linh Nguy-Hoang Le, Irene Abuan, Yvette Leizorek, Sigrid C. Roberts · 2018 · Medical Sciences
Affinity Enhancement of Protein Ligands by Reversible Covalent Modification of Neighboring Lysine Residues
Alberto Dal Corso, Marco Catalano, Anja Sophie Schmid, Jörg Scheuermann, Dario Neri · 2018 · Angewandte Chemie International Edition
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, Philemon, Mirza, Sheefa, Ruff, Paul, Penny, Clement · 2024 · Frontiers in Molecular Biosciences
Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma
Thanh Nguyen, Frederic G. Barr · 2018 · Molecules
Maintaining protein stability of ∆Np63 via USP28 is required by squamous cancer cells
Cristian Prieto‐Garcia, Oliver Hartmann, Michaela Reissland, Fabian Braun, Thomas Fischer, Susanne Walz, Christina Schülein‐Völk, Ursula Eilers, Carsten Patrick Ade, Marco A. Calzado et al. · 2020 · EMBO Molecular Medicine
Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5–MYC Protein–Protein Interaction
Macdonald, Jonathan D., Chacón Simon, Selena, Han, Changho, Wang, Feng, Shaw, J. Grace, Howes, Jennifer E., Sai, Jiqing, Yuh, Joannes P., Camper, Demarco, Alicie, Bethany M. et al. · 2019 · Journal of Medicinal Chemistry
Insulin‐like Growth Factor 2‐Tagged Aptamer Chimeras (ITACs) Modular Assembly for Targeted and Efficient Degradation of Two Membrane Proteins
Yuan Tian, Yanyan Miao, Pei Guo, Junyan Wang, Da Han · 2023 · Angewandte Chemie International Edition
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, Delong, Yang, Shengyu · 2020 · The Innovation
Recent Advances and Perspectives in Cancer Drug Design
Luma G. Magalhães, Leonardo L. G. Ferreira, Adriano Defini Andricopulo · 2018 · Anais da Academia Brasileira de Ciências
TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation
Ke Li, Feng Wang, Zhao-na Yang, Tingting Zhang, Yufen Yuan, Chen-xi Zhao, Zaiwuli Yeerjiang, Bing Cui, Fang Hua, Xiaoxi Lv et al. · 2020 · Nature Communications
Nanomaterials for Protein Delivery in Anticancer Applications
Anne Yau, Jinhyung Lee, Yupeng Chen · 2021 · Pharmaceutics
Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death
Lucia Cottone, Adam P. Cribbs, Garima Khandelwal, Graham Wells, Lorena Ligammari, Martin Philpott, Anthony Tumber, Patrick Lombard, Edward S. Hookway, Tamás Szommer et al. · 2020 · Cancer Research
USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma
Cristian Prieto‐Garcia, Ines Tomašković, Varun Jayeshkumar Shah, Ivan Đikić, Markus E. Diefenbacher · 2021 · Cells
A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions
Le Guo, Yaxian Zhou, Xueqing Nie, Zhongrui Zhang, Zhen Zhang, Chunrong Li, Taobo Wang, Weiping Tang · 2022 · European Journal of Medicinal Chemistry
PAX3-FOXO1: Zooming in on an “undruggable” target
Marco Wachtel, Beat W. Schäfer · 2017 · Seminars in Cancer Biology
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Feixiong Cheng, Han Liang, Atul Janardhan Butte, Charis Eng, Ruth Nussinov · 2018 · Pharmacological Reviews
Histone Deacetylase 11 Contributes to Renal Fibrosis by Repressing KLF15 Transcription
Lei Mao, Li Liu, Tao Zhang, Hao Qin, Xiaoyan Wu, Yong Xu · 2020 · Frontiers in Cell and Developmental Biology
The Ins and Outs of RAS Effector Complexes
Christina Kiel, David Matallanas, Walter Kölch · 2021 · Biomolecules
Photodynamic Therapy for ras -Driven Cancers: Targeting G-Quadruplex RNA Structures with Bifunctional Alkyl-Modified Porphyrins
Annalisa Ferino, Giulia Nicoletto, Francesca D’Este, Sonia Zorzet, Sara Lago, Sara N. Richter, Alexander S. Tikhomirov, Andrey Egorovich Shchekotikhin, Luigi Emilio Xodo · 2020 · Journal of Medicinal Chemistry
Total Synthesis and Target Identification of the Curcusone Diterpenes
Chengsen Cui, Brendan G. Dwyer, Chang Liu, Daniel Abegg, Zhong-Jian Cai, Dominic G. Hoch, Xianglin Yin, Nan Qiu, Jie‐Qing Liu, Alexander Adibekian et al. · 2021 · Journal of the American Chemical Society
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You et al. · 2022 · Acta Pharmaceutica Sinica B
Exploring liver cancer biology through functional genetic screens
Cun Wang, Ying Cao, Chen Guang Yang, René Bernards, Wenxin Qin · 2021 · Nature Reviews Gastroenterology & Hepatology
PROTAC induced-BET protein degradation exhibits potent anti-osteosarcoma activity by triggering apoptosis
Chengcheng Shi, Huapeng Zhang, Penglei Wang, Kai Wang, Denghui Xu, Haitao Wang, Li Yin, Shuijun Zhang, Yi Zhang · 2019 · Cell Death and Disease
Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells
Zhe Sun, Ziheng Zhang, Qiao-Qi Wang, Ji-Long Liu · 2022 · Cancer Research
Screening for molecular glues – Challenges and opportunities
Geoffrey A. Holdgate, Catherine Bardelle, Sophia K. Berry, Alice Lanne, Maria Emanuela Cuomo · 2023 · SLAS DISCOVERY
KRAS: the Achilles’ heel of pancreas cancer biology
Kristina Drizyte‐Miller, Taiwo Talabi, Ashwin Somasundaram, Adrienne D. Cox, Channing J. Der · 2025 · Journal of Clinical Investigation
Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines
Michael R. Pranzatelli · 2018 · Frontiers in Immunology
The paradox of cancer genes in non-malignant conditions: implications for precision medicine
Jacob J. Adashek, Shumei Kato, Scott Michael Lippman, Razelle Kurzrock · 2020 · Genome Medicine
Drug design targeting active posttranslational modification protein isoforms
Fanwang Meng, Zhongjie T. Liang, Kehao Zhao, Cheng Luo · 2020 · Medicinal Research Reviews
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age
Dexter Kai Hao Thng, Tan Boon Toh, Edward Kai‐Hua Chow · 2021 · Trends in Pharmacological Sciences
Regulation of Ferroptosis Pathway by Ubiquitination
Xinbo Wang, Yanjin Wang, Zan Li, Jieling Qin, Ping Wang · 2021 · Frontiers in Cell and Developmental Biology
A Selective Small‐Molecule c‐Myc Degrader Potently Regresses Lethal c‐Myc Overexpressing Tumors
Ying Xu, Qingfeng Yu, Ping Wang, Zhaoxing Wu, Lei Zhang, Shuigao Wu, Mengyuan Li, Bowen Wu, Hongzhi Li, Haifeng Zhuang et al. · 2022 · Advanced Science
Targeting Myc-driven stress addiction in colorectal cancer
Haris Saeed, Brian J. Leibowitz, Lin Zhang, Jian Yu · 2023 · Drug Resistance Updates
Chemoproteomics, A Broad Avenue to Target Deconvolution
Yihui Gao, Mingzhe Ma, Wenyang Li, Xiaoguang Lei · 2023 · Advanced Science
Reliable method for predicting the binding affinity of RNA-small molecule interactions using machine learning
Sowmya Ramaswamy Krishnan, Arijit Roy, M. Michael Gromiha · 2024 · Briefings in Bioinformatics
To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer
Peng Shen, Martin Pichler, Meng Chen, George A. Călin, Hui Yvonne Ling · 2017 · International Journal of Molecular Sciences
Emerging targeted protein degradation tools for innovative drug discovery: From classical PROTACs to the novel and beyond
Yue Zhong, Fanglian Chi, Hanyu Wu, Yunxiao Liu, Zhancheng Xie, Wenlong Huang, Wei Shi, Hai Qian · 2022 · European Journal of Medicinal Chemistry
Synthesis and direct assay of large macrocycle diversities by combinatorial late-stage modification at picomole scale
Sevan Habeshian, Manuel L. Merz, Gontran Sangouard, Mothukuri Ganesh Kumar, Mischa Schüttel, Zsolt Bognár, Cristina Díaz‐Perlas, Jonathan Vesin, Julien Bortoli Chapalay, Gerardo Turcatti et al. · 2022 · Nature Communications
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Khalil Choucair, Hafsa Imtiaz, Md. Hafiz Uddin, Misako Nagasaka, Mohammad Najeeb Al-Hallak, Philip A. Philip, Bassel El-Rayes, Boris Pasche, Asfar Sohail Azmi · 2025 · Signal Transduction and Targeted Therapy
A Case of Identity: HOX Genes in Normal and Cancer Stem Cells
Jessica Smith, Ahmad Zyoud, C. Allegrucci · 2019 · Cancers
TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain
Moses M. Kasembeli, Pooja Singhmar, Jiacheng Ma, Jules D. Edralin, Yongfu Tang, Clydell Adams, Cobi J. Heijnen, Annemieke Kavelaars, David John Tweardy · 2021 · Biochemical Pharmacology
Nanocarriers escaping from hyperacidified endo/lysosomes in cancer cells allow tumor-targeted intracellular delivery of antibodies to therapeutically inhibit c-MYC
Pengwen Chen, Wenqian Yang, Taehun Hong, Takuya Miyazaki, Anjaneyulu Dirisala, Kazunori Kataoka, Horacio Cabral · 2022 · Biomaterials
Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc Protein
Yuchun Wang, Gang Yang, Xinyu Zhang, Ruoling Bai, Deyu Yuan, Denghui Gao, Qianyu He, Yi Yuan, Xinghe Zhang, Junchuang Kou et al. · 2024 · Advanced Science
An overview of recent molecular dynamics applications as medicinal chemistry tools for the undruggable site challenge
Ugo Perricone, Maria Rita Gulotta, Jessica Lombino, Barbara Parrino, Stella Cascioferro, Patrizia Diana, Girolamo Cirrincione, Alessandro Padova · 2018 · MedChemComm
The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology
Fengjuan Fan, Klaus Podar · 2021 · Cancers
Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery
Rocío Marisol Espinoza-Chávez, Alessandra Salerno, Anastasia Liuzzi, Andrea Ilari, Andrea Milelli, Elisa Uliassi, María Laura Bolognesi · 2022 · ACS Bio & Med Chem Au
Demystifying the Druggability of the MYC Family of Oncogenes
Nishant M. Karadkhelkar, Mingliang Lin, Lisa M. Eubanks, Kim D. Janda · 2023 · Journal of the American Chemical Society
TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer
Wen-Long Ye, Long Huang, Xiaoqin Yang, Shan Wan, Wen-Juan Gan, Yun Yang, Xiaoshun He, Feng Liu, Xin Guo, Yi-Xuan Liu et al. · 2024 · Proceedings of the National Academy of Sciences
Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
Liwen Xia, Meng-Yu Ba, Wei Liu, Weyland Cheng, Chao-Ping Hu, Qing Zhao, Yongfang Yao, Moran Sun, Yongtao Duan · 2019 · Future Medicinal Chemistry
Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer
Junru Feng, Hui Juan Lu, Wenhao Ma, Wenjing Tian, Zhuan Lu, Hongying Yang, Yongping Cai, Pengfei Cai, Yuchen Sun, Zilong Zhou et al. · 2022 · Protein & Cell